DexCom, Inc. - Common Stock (DXCM)
59.08
-9.12 (-13.37%)
NASDAQ · Last Trade: Oct 31st, 3:29 PM EDT
Shares of medical device company DexCom (NASDAQ:DXCM)
 fell 14.8% in the afternoon session after the company reported underwhelming earnings. 
Via StockStory · October 31, 2025
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · October 31, 2025
The diabetes equipment provider had a strong quarter, but next year is looking weaker than expected.
Via The Motley Fool · October 31, 2025
Friday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
Via Chartmill · October 31, 2025
Dexcom Stock Plunges 13% After-Hours As Q3 Margin Pressures Eclipse Record Profit — Retail Sees ‘Buy The Dip’ Setupdexcom
Via Stocktwits · October 30, 2025
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive.
Via Benzinga · October 31, 2025
Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to analysts’ estimates. Its non-GAAP profit of $0.61 per share was 7.5% above analysts’ consensus estimates. 
Via StockStory · October 31, 2025
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Via Chartmill · October 31, 2025
Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.
Via Investor's Business Daily · October 31, 2025
Via Benzinga · October 31, 2025
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.
Via Chartmill · October 30, 2025
DexCom Q3 2025 earnings beat estimates, but stock fell due to full-year revenue guidance that missed analyst expectations.
Via Chartmill · October 30, 2025
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q3 CY2025, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to analysts’ estimates. Its non-GAAP profit of $0.61 per share was 7.5% above analysts’ consensus estimates. 
Via StockStory · October 30, 2025
Via Benzinga · October 30, 2025
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th
Via Benzinga · October 30, 2025
The company hasn't had a great year. Is it about to turn things around?
Via The Motley Fool · October 30, 2025
Medical device company DexCom (NASDAQ:DXCM)
 will be reporting results this Thursday after market close. Here’s what you need to know. 
Via StockStory · October 28, 2025
Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.
Via Benzinga · October 28, 2025
Short seller Hunterbrook stated that at least 13 G7 users have died since the device launched in 2023. 
Via Stocktwits · October 28, 2025
Via Benzinga · October 21, 2025
Both companies have faced recent challenges, but look likely to overcome them.
Via The Motley Fool · October 14, 2025
Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q2 patient monitoring earnings season. 
Via StockStory · October 13, 2025